APGE · As filed with the SEC
Apogee Therapeutics income statement, by quarter
The statement as Apogee Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 67,301,000 | 60,819,000 | — | 54,178,000 |
| General and administrative | 24,342,000 | 21,953,000 | — | 17,100,000 |
| Merger transaction costs | 4,361,000 | — | — | — |
| Total operating expenses | 96,004,000 | 82,772,000 | — | 71,278,000 |
| Loss from operations | (96,004,000) | (82,772,000) | — | (71,278,000) |
| Other income, net: | ||||
| Interest income, net | 11,808,000 | 8,740,000 | — | 6,318,000 |
| Interest expense | (1,580,000) | — | — | — |
| Total other income, net | 10,228,000 | 8,740,000 | — | 6,318,000 |
| Net loss before taxes | (85,776,000) | (74,032,000) | — | (64,960,000) |
| Provision for income taxes | (78,000) | (79,000) | — | (61,000) |
| Net loss after taxes | (85,854,000) | (74,111,000) | — | (65,021,000) |
| Net loss per share, basic | (1.14) | (1.06) | — | (1.11) |
| Net loss per share, diluted | (1.14) | (1.06) | — | (1.11) |
| Weighted-average common shares outstanding, basic | 75,443,496 | 69,668,439 | — | 58,773,731 |
| Weighted-average common shares outstanding, diluted | 75,443,496 | 69,668,439 | — | 58,773,731 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.